Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence

Emicizumab, a humanized, bi-specific, monoclonal antibody subcutaneously administered, mimicking the function of FVIIIa, represents a milestone in treatment of patients affected by hemophilia A complicated with inhibitors. The HAVEN 1 and 2 studies have clearly established its superiority compared t...

Descripción completa

Detalles Bibliográficos
Autores principales: Linari, Silvia, Castaman, Giancarlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251291/
https://www.ncbi.nlm.nih.gov/pubmed/32547043
http://dx.doi.org/10.2147/TCRM.S205310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251291/
https://www.ncbi.nlm.nih.gov/pubmed/32547043
http://dx.doi.org/10.2147/TCRM.S205310

Ejemplares similares